Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

We have selected an HXB2 variant which can replicate in the presence of a neutralizing human serum. Sequencing of the gp120 region of the env gene from the variant and parental viruses identified a single amino acid substitution in the third conserved region of gp120 at residue 375 (AGT-->AAT, Ser-->Asn; designated 375 S/N). The escape mutant was found to be resistant to neutralization by soluble CD4 (sCD4) and four monoclonal antibodies (MAbs), 39.13g, 1.5e, G13, and 448, binding to epitopes overlapping that of the CD4 binding site (CD4 b.s.). Introduction of the 375 S/N mutation into HXB2 by site-directed mutagenesis confirmed that this mutation is responsible for the neutralization-resistant phenotype. Both sCD4 and three of the CD4 b.s. MAbs (39.13g, 1.5e, and G13) demonstrated reduced binding to the native 375 S/N mutant gp120. The ability to select for an escape variant resistant to multiple independent CD4 b.s. MAbs by a human serum confirms the reports that antibodies to the discontinuous CD4 b.s. are a major component of the group-specific neutralizing activity in human sera.

Type

Journal article

Journal

J Virol

Publication Date

09/1993

Volume

67

Pages

5216 - 5225

Keywords

Amino Acid Sequence, Antibodies, Monoclonal, Antigens, CD, Base Sequence, Binding Sites, CD4 Antigens, Cell Line, Cloning, Molecular, Conserved Sequence, Epitopes, HIV Envelope Protein gp120, HIV-1, Humans, Ligands, Molecular Sequence Data, Mutagenesis, Site-Directed, Neutralization Tests, Oligodeoxyribonucleotides, Point Mutation, Recombinant Proteins, Restriction Mapping, Transfection